Key result
Complementary approaches using in silico simulations, transgenic rabbits, and hiPSC-CMs consistently demonstrate that the N588K-hERG mutation increases IKr, shortens action potential duration, and increases susceptibility to re-entry in Short QT Syndrome.
Why the study?
Congenital Short QT Syndrome (SQTS) is a rare, dangerous condition involving abbreviated ventricular repolarization and arrhythmia risk, prompting examination of basic science approaches used to understand arrhythmogenesis mechanisms in N588K-hERG-linked SQTS.
Multiple complementary basic science approaches consistently demonstrate that the N588K-hERG mutation causes abbreviated repolarization and increased susceptibility to re-entry, which can be mitigated by Class Ia antiarrhythmic drugs.
May guide mechanism-based therapy development in Short QT Syndrome; hypothesis-generating and leaves open clinical translation.
Congenital Short QT Syndrome (SQTS) is a rare but dangerous condition involving abbreviated ventricular repolarization and an increased risk of atrial and ventricular arrhythmias. Taking the example of the first identified SQTS mutation, N588K-hERG, we consider briefly the basic science approaches used to obtain an understanding of the mechanism(s) of arrhythmogenesis in this form of the syndrome. A combination of recombinant channel electrophysiology and in silico simulations has provided insights into causality between the identified mutation, accelerated repolarization and increased susceptibility to re-entry in N588K-hERG-linked SQTS. Subsequent studies employing a transgenic rabbit model or human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) have further demonstrated mechanisms predisposing to re-entry, spiral wave activity and arrhythmia in intact tissue. The complementarity between the findings made using these different approaches gives confidence that, collectively, they have identified major arrhythmia mechanisms and their potential mitigation by Class I antiarrhythmic drugs in this form of SQTS.
No takes yet. Share an insight, caveat, or question.
Hancox et al. (2020) conducted a review in Short QT Syndrome. N588K-hERG mutation models was evaluated. Complementary approaches using in silico simulations, transgenic rabbits, and hiPSC-CMs consistently demonstrate that the N588K-hERG mutation increases IKr, shortens action potential duration, and increases susceptibility to re-entry in Short QT Syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: